Omiganan - Cutanea Life Sciences

Drug Profile

Omiganan - Cutanea Life Sciences

Alternative Names: CLS-001; CPI-226; MBI-226; MBI-594AN; MX-226; MX-594AN; Omiganan pentachloride; Omiganan pentahydrochloride; Omiganan pentahydrochloride 1% gel; Omigard

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MIGENIX
  • Developer Cadence Pharmaceuticals; Carrus Capital Corporation; Cutanea Life Sciences
  • Class Antibacterials; Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Phase III Rosacea
  • Phase II Acne vulgaris; Atopic dermatitis; Condylomata acuminata; Seborrhoeic dermatitis; Vulvar intraepithelial neoplasia
  • Phase I Dermatitis
  • Discontinued Catheter infections

Most Recent Events

  • 05 Oct 2018 Cutanea Life Sciences plans a phase II trial for Seborrheic dermatitis (In adults, In the elderly) in Netherlands (Topical) (NCT03688971)
  • 05 Sep 2018 Phase-II clinical trials in Seborrhoeic dermatitis (In adults, In the elderly) in Netherlands (Topical) (EudraCT2017-003106-41)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top